JP2025063123A5 - - Google Patents
Info
- Publication number
- JP2025063123A5 JP2025063123A5 JP2025002212A JP2025002212A JP2025063123A5 JP 2025063123 A5 JP2025063123 A5 JP 2025063123A5 JP 2025002212 A JP2025002212 A JP 2025002212A JP 2025002212 A JP2025002212 A JP 2025002212A JP 2025063123 A5 JP2025063123 A5 JP 2025063123A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- fusion protein
- identity
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862695623P | 2018-07-09 | 2018-07-09 | |
| US201862695627P | 2018-07-09 | 2018-07-09 | |
| US62/695,623 | 2018-07-09 | ||
| US62/695,627 | 2018-07-09 | ||
| US201962863710P | 2019-06-19 | 2019-06-19 | |
| US62/863,710 | 2019-06-19 | ||
| US201962864367P | 2019-06-20 | 2019-06-20 | |
| US62/864,367 | 2019-06-20 | ||
| US201962866420P | 2019-06-25 | 2019-06-25 | |
| US62/866,420 | 2019-06-25 | ||
| PCT/US2019/041085 WO2020014285A2 (en) | 2018-07-09 | 2019-07-09 | Fusion constructs and methods of using thereof |
| JP2021500735A JP7617839B2 (ja) | 2018-07-09 | 2019-07-09 | 融合構築物およびその使用法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500735A Division JP7617839B2 (ja) | 2018-07-09 | 2019-07-09 | 融合構築物およびその使用法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025063123A JP2025063123A (ja) | 2025-04-15 |
| JP2025063123A5 true JP2025063123A5 (https=) | 2025-09-12 |
Family
ID=69141640
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500735A Active JP7617839B2 (ja) | 2018-07-09 | 2019-07-09 | 融合構築物およびその使用法 |
| JP2025002212A Pending JP2025063123A (ja) | 2018-07-09 | 2025-01-07 | 融合構築物およびその使用法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500735A Active JP7617839B2 (ja) | 2018-07-09 | 2019-07-09 | 融合構築物およびその使用法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11535669B2 (https=) |
| EP (1) | EP3820496A4 (https=) |
| JP (2) | JP7617839B2 (https=) |
| KR (1) | KR20210042909A (https=) |
| CN (2) | CN112672753B (https=) |
| AU (1) | AU2019301070B2 (https=) |
| CA (1) | CA3105750A1 (https=) |
| IL (1) | IL279965A (https=) |
| SG (1) | SG11202100208VA (https=) |
| WO (1) | WO2020014285A2 (https=) |
| ZA (2) | ZA202100390B (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| EP3697438A4 (en) * | 2017-10-18 | 2021-08-18 | Intrexon Corporation | POLYPEPTIDE COMPOSITIONS WITH SPACERS |
| BR112021012027A2 (pt) * | 2018-12-21 | 2021-11-03 | Ose Immunotherapeutics | Molécula bifuncional direcionada contra pd-1 humano |
| CN110734498A (zh) * | 2019-10-15 | 2020-01-31 | 上海科棋药业科技有限公司 | 一种用于解除免疫抑制的融合蛋白及其应用 |
| US11802145B2 (en) | 2019-10-21 | 2023-10-31 | Nanjing Leads Biolabs Co., Ltd. | Recombinant protein targeting PD-1 and TGFß |
| EP4051279A1 (en) | 2019-11-01 | 2022-09-07 | Ares Trading S.A. | COMBINED INHIBITION OF PD-1, TGFß AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER |
| EP4054633A1 (en) | 2019-11-05 | 2022-09-14 | Merck Patent GmbH | Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer |
| CN115397973A (zh) * | 2020-01-30 | 2022-11-25 | 免疫生物公司 | 表达car的nk细胞消除bcma阳性恶性肿瘤 |
| KR20220107257A (ko) * | 2020-03-20 | 2022-08-02 | 레메젠 코, 리미티드 | 이중특이성 융합 단백질 및 그의 응용 |
| AU2021256925A1 (en) | 2020-04-14 | 2022-11-03 | Ares Trading S.A. | Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein |
| WO2021209458A1 (en) | 2020-04-14 | 2021-10-21 | Ares Trading S.A. | Combination treatment of cancer |
| US20230235057A1 (en) * | 2020-04-29 | 2023-07-27 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Bifunctional protein against pd-1 and tgf-beta |
| WO2021231773A1 (en) | 2020-05-13 | 2021-11-18 | Good Therapeutics, Inc. | Compositions of protein complexes and methods of use thereof |
| CN113754771A (zh) * | 2020-06-02 | 2021-12-07 | 三生国健药业（上海）股份有限公司 | 一种抗pdl1×egfr的双特异性抗体 |
| MX2023000005A (es) * | 2020-06-26 | 2023-03-06 | Sorrento Therapeutics Inc | Virus del herpes simple (vhs) oncolíticos que expresan proteínas de fusión inmunomoduladoras. |
| EP4178680A4 (en) * | 2020-07-10 | 2024-07-31 | Precigen, Inc. | FUSION CONSTRUCTS AND THEIR METHODS OF USE |
| WO2022063314A1 (zh) * | 2020-09-28 | 2022-03-31 | 上海君实生物医药科技股份有限公司 | 靶向PD-1或PD-L1和TGF-β的双功能蛋白及其医药用途 |
| WO2022090527A1 (en) | 2020-11-02 | 2022-05-05 | Ares Trading S.A. | Combination treatment of cancer |
| US20230372319A1 (en) | 2020-11-02 | 2023-11-23 | Ares Trading S.A. | Combination Treatment of Cancer |
| US20230416394A1 (en) * | 2020-11-27 | 2023-12-28 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel conjugate molecules targeting cd39 and tgfbeta |
| EP4291227A2 (en) * | 2021-02-15 | 2023-12-20 | Takeda Pharmaceutical Company Limited | Cell therapy compositions and methods for modulating tgf-b signaling |
| CN116917334B (zh) * | 2021-02-22 | 2026-02-06 | 浙江道尔生物科技有限公司 | 一种具有抗癌活性的多结构域融合蛋白 |
| CN112979802B (zh) * | 2021-04-21 | 2021-08-03 | 上海普铭生物科技有限公司 | 抗人il-33单克隆抗体及其应用 |
| CN113249330A (zh) * | 2021-05-20 | 2021-08-13 | 深圳市先康达生命科学有限公司 | 免疫细胞及其应用 |
| WO2022258622A1 (en) | 2021-06-07 | 2022-12-15 | Ares Trading S.A. | Combination treatment of cancer |
| WO2023034742A1 (en) * | 2021-08-30 | 2023-03-09 | The Board Of Trustees Of The Leland Stanford Junior University | T cells with cell-surface expression of adenosine deaminase and uses thereof |
| JP2024533109A (ja) * | 2021-08-31 | 2024-09-12 | ザ テキサス エーアンドエム ユニヴァーシティ システム | キメラ抗原受容体（ｃａｒ）ｔ細胞療法プラットフォーム |
| US20240391990A1 (en) * | 2021-09-03 | 2024-11-28 | Nan TANG | Bi-functional fusion protein and uses thereof |
| WO2023086920A2 (en) * | 2021-11-12 | 2023-05-19 | Georgia Tech Research Corporation | Adenosine deaminase 2 compositions and methods for using same |
| CN118339187A (zh) * | 2021-12-31 | 2024-07-12 | 上海宏成药业有限公司 | 抗pd-1抗体及其用途 |
| CN114540311A (zh) * | 2022-02-24 | 2022-05-27 | 深圳市先康达生命科学有限公司 | 一种免疫细胞及其应用 |
| CN116041539B (zh) * | 2022-10-31 | 2023-07-21 | 山东博安生物技术股份有限公司 | Il-2突变体免疫缀合物 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| EP0973888A1 (en) | 1997-02-06 | 2000-01-26 | Human Genome Sciences, Inc. | Dendritic cell-derived growth factor |
| JP2001515360A (ja) | 1997-04-18 | 2001-09-18 | バイオジェン，インコーポレイテッド | ▲ＩＩ▼型ＴＧＦ−βレセプター／免疫グロブリン定常領域融合タンパク質 |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| RU2494107C2 (ru) * | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| US20110245174A1 (en) * | 2008-08-21 | 2011-10-06 | Peter Artymiuk | Glp-1 fusion polypeptides |
| CA3083324A1 (en) * | 2010-03-05 | 2011-09-09 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| US20150086584A1 (en) | 2012-03-22 | 2015-03-26 | University Of Miami | Multi-specific binding agents |
| CN110563850A (zh) | 2012-04-30 | 2019-12-13 | 比奥孔有限公司 | 靶向/免疫调节性融合蛋白及其制造方法 |
| WO2013169693A1 (en) * | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody |
| US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
| EP3783098A1 (en) | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| CA2920113A1 (en) * | 2013-08-20 | 2015-02-26 | Merck Sharp & Dohme Corp. | Treating cancer with a combination of a pd-1 antagonist and dinaciclib |
| CA2921805C (en) | 2013-08-22 | 2023-03-07 | Acceleron Pharma, Inc. | Tgf-beta receptor type ii variants and uses thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| US9676863B2 (en) | 2014-02-10 | 2017-06-13 | Merck Patent Gmbh | Targeted TGFβ inhibitors |
| KR20160145802A (ko) | 2014-04-23 | 2016-12-20 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 요법에 사용하기 위한 키메라 항원 수용체 (car) 및 이의 제조 방법 |
| ES2753391T3 (es) | 2014-10-14 | 2020-04-08 | Halozyme Inc | Composiciones de adenosina desaminasa 2 (ADA2), variantes de la misma y métodos de uso de las mismas |
| KR20190003938A (ko) | 2016-02-25 | 2019-01-10 | 셀 메디카 스위처란트 아게 | 면역치료를 위한 변형된 세포 |
| EP3487998B1 (en) * | 2016-07-19 | 2023-07-12 | Brandeis University | Compositions and methods for identifying rna binding polypeptide targets |
| EP3497130B1 (en) | 2016-08-12 | 2021-10-27 | Merck Patent GmbH | Combination therapy for cancer |
| CN118307682A (zh) | 2016-09-27 | 2024-07-09 | 埃皮辛特瑞柯斯公司 | 免疫调节性融合蛋白 |
| WO2018129331A1 (en) | 2017-01-07 | 2018-07-12 | Merck Patent Gmbh | Dosing regimens and dosage forms for targeted tgf-b inhibition |
| LT3628049T (lt) | 2017-05-04 | 2023-08-25 | Acceleron Pharma Inc. | Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai |
| JP7340458B2 (ja) | 2017-05-09 | 2023-09-07 | アメリカ合衆国 | Ｈｐｖ＋悪性腫瘍を有する患者におけるｐｄｌ１とｔｇｆベータの遮断の組み合わせ |
| AU2018264455B2 (en) | 2017-05-12 | 2024-12-12 | Jiangsu Hengrui Medicine Co., Ltd. | Fusion protein containing TGF-beta receptor and medicinal uses thereof |
| CN112512576A (zh) | 2018-05-04 | 2021-03-16 | 默克专利有限公司 | PD-1/PD-L1、TGFβ和DNA-PK联合抑制用于治疗癌症 |
| WO2020118094A1 (en) * | 2018-12-06 | 2020-06-11 | Guangdong Tcrcure Biopharma Technology Co., Ltd. | Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints |
| CN109913425B (zh) * | 2019-03-22 | 2021-05-11 | 中国人民解放军总医院第五医学中心 | 一种重组流感病毒拯救方法及其在肿瘤治疗中的应用 |
| CN114555099A (zh) * | 2019-06-23 | 2022-05-27 | 广东天科雅生物医药科技有限公司 | 抗alpp car-t细胞疗法 |
-
2019
- 2019-07-09 WO PCT/US2019/041085 patent/WO2020014285A2/en not_active Ceased
- 2019-07-09 SG SG11202100208VA patent/SG11202100208VA/en unknown
- 2019-07-09 EP EP19834221.4A patent/EP3820496A4/en active Pending
- 2019-07-09 AU AU2019301070A patent/AU2019301070B2/en active Active
- 2019-07-09 JP JP2021500735A patent/JP7617839B2/ja active Active
- 2019-07-09 US US16/506,981 patent/US11535669B2/en active Active
- 2019-07-09 CN CN201980058963.8A patent/CN112672753B/zh active Active
- 2019-07-09 CA CA3105750A patent/CA3105750A1/en active Pending
- 2019-07-09 KR KR1020217003783A patent/KR20210042909A/ko not_active Ceased
- 2019-07-09 CN CN202510846429.0A patent/CN120775065A/zh active Pending
-
2021
- 2021-01-05 IL IL279965A patent/IL279965A/en unknown
- 2021-01-19 ZA ZA2021/00390A patent/ZA202100390B/en unknown
-
2022
- 2022-11-23 US US18/058,364 patent/US20240141045A1/en active Pending
-
2023
- 2023-01-10 ZA ZA2023/00423A patent/ZA202300423B/en unknown
-
2025
- 2025-01-07 JP JP2025002212A patent/JP2025063123A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025063123A5 (https=) | ||
| JP2021531754A5 (https=) | ||
| AU2003209447B8 (en) | RS7 antibodies | |
| JP2020531043A5 (https=) | ||
| JP2020501531A5 (https=) | ||
| Xiong et al. | Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20× anti-CD3 bispecific diabody | |
| CN111148761A (zh) | 多特异性抗体及其制备和使用方法 | |
| US20250034273A1 (en) | Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof | |
| JPWO2020014285A5 (https=) | ||
| CN116199785A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2021512604A5 (https=) | ||
| KR20220042258A (ko) | 항 tigit 항체 및 그의 응용 | |
| JP2022521305A (ja) | 抗ｐｄ－ｌ１抗体及びその使用 | |
| Espinosa-Cotton et al. | Bispecific antibodies for the treatment of neuroblastoma | |
| JP2024020436A5 (https=) | ||
| CA3180690A1 (en) | Cd38 antibodies for treatment of human diseases | |
| JP2025503229A (ja) | 抗ｈｅｒ２／ｔｒｏｐ２抗体及びその使用 | |
| US20240228658A1 (en) | Anti-5t4 antibodies and uses thereof | |
| CN107108735B (zh) | 新型egfrviii抗体和包含所述抗体的组合物 | |
| JPWO2022067262A5 (https=) | ||
| EP4667491A1 (en) | Anti-cntn4 antibody and uses thereof | |
| JPWO2021068841A5 (https=) | ||
| JPWO2019152895A5 (https=) | ||
| IL321677A (en) | Anti-PDL1 antibodies, multispecific antibodies, and methods of use | |
| JPWO2021247769A5 (https=) |